Anticoagulation with bivalirudin is associated with improved biocompatibility in patients supported on microaxial flow pumpsCentral MessagePerspective

Objective: To evaluate whether an institutional shift from anticoagulation with heparin to bivalirudin in Impella 5.5 patients altered bleeding or thrombotic rates, transfusion dependency, or device biocompatibility. Methods: All patients supported by an Impella 5.5 between August 2022 and December...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής

Κύριοι συγγραφείς:	Michaela Asher, MPhil, Emma Morganroth, BS, Amit Iyengar, MD, MSE, Michael Catalano, MD, Cindy Song, MD, David Rekhtman, MD, Max Shin, MD, Omar Toubat, MD, PhD, Samuel Kim, MD, Alyson Brown, BA, Joyce Wald, DO, Aditya Parikh, MD, Mauer Biscotti, MD, Marisa Cevasco, MD, MPH
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	Elsevier 2026-04-01
Σειρά:	JTCVS Open
Θέματα:	Impella 5.5 bivalirudin heparin MCS transplant heart failure
Διαθέσιμο Online:	http://www.sciencedirect.com/science/article/pii/S2666273626001269
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!